The Cancer Research Institute Clinical Innovator Grant supports investigator-led Phase I/II or Phase II trials testing innovative cancer immunotherapies. Studies should generate insights into treatment response and predictive biomarkers. Chordoma-focused proposals are also welcomed through CRI’s partnership with the Chordoma Foundation.
Eligibility Criteria
- Applicants must be the principal investigator of the proposed study.
- Research must take place at a nonprofit medical school or research center.
- Institutions worldwide are eligible, with no citizenship restrictions.
- Proposals must address innovative cancer immunotherapy clinical research.
Funding Details
- Up to $1 million per trial.
- Up to 10% additional indirect costs.
- Covers investigator salary, patient costs, supplies, correlative assays and data analysis.
- Payments are linked to milestones.
Deadline
- Initial Protocol Concept: December 1, 2026.
- Invited full proposal: April 1, 2027.
- Submissions close at 11:59 p.m. Eastern Time.